The Fourteenth Eilat Conference on New Antiepileptic Drugs and Devices (EILAT XIV) took place in Madrid, Spain, on May 13-16, 2018 and was attended by 168 delegates from 28 countries. The conference provided a forum for professionals involved in basic science, clinical research, regulatory affairs, and clinical care to meet and discuss the latest advances related to discovery and development of drugs and devices aimed at improving the management of people with epilepsy. This progress report provides a summary of findings on investigational compounds for which data from preclinical or early (phase I) clinical studies were presented. The compounds reviewed include adenosine and adenosine kinase inhibitors, BIS-001 (huperzine A), 2-deoxy-D-glucose, FV-082, FV-137, JNJ-40411813, JNJ-55511118 and analogs, ketone-enhanced antiepileptic drugs, oxynytones, OV329, TAK-935 (OV935), XEN901, and XEN1101. Many innovative approaches to drug development were presented. For example, some compounds are being combined with traditional antiepileptic drugs based on evidence of synergism in seizure models, some act as inhibitors of enzymes involved in modulation of neuronal activity, and some interact in novel ways with excitatory receptors or ion channels. Some of the compounds in development target the etiology of specific epilepsy syndromes (including orphan conditions) through precision medicine, and some offer hope of producing disease-modifying effects rather than symptomatic seizure suppression. Overall, the results summarized in the report indicate that important advances are being made in the effort to develop compounds with potentially improved efficacy and safety profiles compared with existing agents.
| INTRODUCTION
The Fourteenth Eilat Conference on New Antiepileptic Drugs and Devices (EILAT XIV) took place in Madrid, Spain, on May 13-16, 2018 and was attended by 168 delegates from 28 countries. Attendees included epileptologists, general neurologists, pediatricians, clinical pharmacologists, and basic scientists, and comprised professionals working in clinical care, academia, nonprofit research organizations, and industry. For the past 26 years, Eilat conferences have provided a unique opportunity for stakeholders interested in the development of new epilepsy treatments to meet and discuss the latest advances in understanding the mechanisms of epileptogenesis, seizure generation and propagation, and potential strategies to inhibit and reverse these processes. Topics discussed at EILAT XIV included new animal models of seizures and epilepsy (including models of pharmacoresistance and models of genetic epilepsies), translational aspects of rational drug discovery, preclinical approaches to the study of seizure suppression through neuromodulation, optimized trial designs for the clinical assessment of drugs and medical devices, and the economic challenges associated with development of treatments for rare diseases.
As per tradition, a major part of the conference was dedicated to the presentation of recent findings concerning antiepileptic drugs (AEDs) currently in development. To obtain an overview as comprehensive as possible of ongoing progress in AED development, the members of the EILAT XIV organizing committee (primary authors of this report) used all information available to them, including information derived from literature searches, consultation with colleagues, and websites (including clinicaltrials.gov), to identify compounds being developed as potential epilepsy treatments, and to select presenters. For products developed by the pharmaceutical industry, presenters were typically selected in consultation with the company responsible for development. The presenters of bumetanide and bumetanide derivatives, cerliponase alfa (BMN190), imepitoin, and novel mTOR inhibitors, which were also included in the conference's program, declined to provide a summary or were unable to submit it by the deadline set for the finalization of the manuscript.
The present article summarizes data on 13 compounds or classes of compounds for which results from preclinical and early (phase I) clinical development were presented. These include adenosine and adenosine kinase (ADK) inhibitors, BIS-001 (huperzine A), 2-deoxy-D-glucose, FV-082, FV-137, JNJ-40411813, JNJ-55511118 and analogs, ketone-enhanced antiepileptic drugs, OV329, oxynytones, TAK-935 (OV935), XEN901, and XEN1101. Information on potential AEDs in more advanced development is presented in an accompanying article. 1 
| ADENOSINE AND ADK

INHIBITORS
Detlev Boison
1 and Kenneth A. Jacobson
• The Eilat Conference on New Antiepileptic Drugs and Devices is a biannual event focused on discussing advances in the development of new treatments for epilepsy • The Fourteenth Conference took place in Madrid, Spain, on May 13-16, 2018 and was attended by 168 scientists from 28 countries • This article summarizes findings presented at the conference for 13 compounds (or classes of compounds) currently in preclinical or early clinical development • Innovative development strategies were presented, including combining new molecules with traditional AEDs based on preclinical evidence of synergism, inhibiting enzymes involved in modulation of neuronal activity, and interacting in novel ways with excitatory receptors or ion channels • Overall, the data indicate that there is renewed interest in AED drug discovery and that several compounds with promising pharmacological profiles are being developed
| Introduction and rationale for development
Epilepsy and its progression can be prevented by the transient augmentation of adenosine. We have shown that overexpression of the major adenosine regulating enzyme ADK and resulting adenosine deficiency and epigenetic changes contribute to the epileptogenic process. 2, 3 Consequently, our past research efforts have demonstrated that both focal adenosine augmentation through local adenosine-releasing silkor cell-based brain implants [3] [4] [5] and systemic adenosine augmentation through a small molecule ADK inhibitor can modify epilepsy development or delay its progression in etiologically different rodent systems that model epileptogenesis in temporal lobe epilepsy, our clinical target. We have shown that therapeutic adenosine augmentation prevents kindling epileptogenesis in the rat, prevents epilepsy development in the mouse intra-amygdaloid and intrahippocampal kainic acid models, and prevents epilepsy progression in the rat systemic kainic acid model. 2, 3, 5 We demonstrated that the robust antiepileptogenic effects of adenosine are based on an epigenetic mechanism, whereby increased levels of adenosine reduce global DNA methylation levels through mass action. 3 It is now well established that maladaptive changes in DNA methylation contribute to epileptogenesis and disease progression. 3, 6 Consequently, interrupting epigenetic processes that promote a hypermethylated state of DNA through adenosine augmentation are antiepileptogenic. 3 A driving force for pathological increases in DNA methylation status is maladaptive changes in adenosine metabolism triggered by pathological overexpression of the adenosine-metabolizing enzyme ADK. 2, 3 ADK is a ribokinase (not related to protein kinases) that adds a phosphate group to the ribose moiety of adenosine and thereby turns adenosine into adenosine monophosphate. Whereas drug development previously targeted cytoplasmic ADK-S to enhance adenosine receptor activation, we demonstrated recently that ADK-L, a specific ADK isoform located in the nucleus of the cell, plays a key role in the regulation of adenosine receptor independent epigenetic functions of adenosine. 3 In line with those findings, we demonstrated that 5-day treatment with the small molecule ADK inhibitor 5-iodotubercidin (5-ITU), 1.6 mg/kg twice daily (b.i.d.) intraperitoneally (ip), initiated 3 days after triggering epileptogenesis through intrahippocampal kainic acid, prevented the development of seizures in >50% of all mice. 7 Because ADK is overexpressed in the epileptic brain and associated with epileptogenesis, 3, 8 there is a strong rationale for the clinical development of ADK inhibitors that restore normal adenosine function. The development and validation of new ADK inhibitors that mobilize long-lasting antiepileptogenic epigenetic effects through transient ADK-L inhibition may enhance the contribution of desirable epigenetically based antiepileptogenic effects of adenosine. Shortterm use of ADK inhibitors may mitigate risks of chronic ADK inhibition related to liver toxicity. We recently identified MRS4203 as a promising lead for the development of adenosine-enhancing antiepileptogenic therapies. 9 
| Pharmacology
The anticonvulsant and antiepileptogenic properties of adenosine have been described in detail in the EILAT XII and EILAT XIII progress reports, respectively, 7,10 and the rationale for developing ADK inhibitors as potential antiepileptogenic agents has been discussed above.
We recently designed synthetic approaches to both ringconstrained south (S)-and north (N)-methano-carba-7-deaza-adenosine analogues 9 of the ADK inhibitor 5-ITU, which demonstrated antiepileptogenic activity in our model system. 7 Those approaches led to the identification of our lead compound MRS4203, which is an (S) analogue.
9
MRS4203 exhibited potent ADK inhibition, with a halfmaximal inhibitory concentration (IC 50 ) value of 88 nmol/ L. 9 We demonstrated that MRS4203 at a 26 nmol/L concentration reduced global DNA methylation by >50% in genetically engineered ADK-L cells that only express ADK-L, but do not express ADK-S. In contrast, MRS4203 had no activity in ADK-S cells (which only express ADK-S, but lack ADK-L). Likewise, MRS4203 had no effects in ADK-deficient ADK-null cells. Those findings suggest that MRS4203 exerts epigenetic activity specifically through blockade of ADK-L without any obvious off-target effects.
In healthy adult mice, three injections of MRS4203 (3.1 mg/kg ip) delivered every 12 hours reduced DNA methyl transferase activity and DNA methylation in the brain, showing that inhibition of ADK-L activity by MRS4203 in vitro is associated with reduced DNA methylation in vivo. Importantly, DNA methyl transferase activity was analyzed 1 hour after the third drug injection, suggesting that MRS4203 administered systemically can affect DNA methylation in the brain. MRS4203 was not associated with any overt signs of sedation, whereas an equal dose of the nonselective parent ADK inhibitor 5-ITU had major sedative effects that immobilized the animals. We conclude that MRS4203 exerts epigenetic activity in the brain without causing side effects associated with 5-ITU.
| Mechanisms of action
The mechanisms responsible for the antiepileptogenic properties of adenosine have been summarized in previous reports. 7, 10 The antiepileptogenic mechanism of MRS4203 is to inhibit ADK in the cell nucleus, thereby blocking the flux of methylation reactions through the S-adenosylmethionine-dependent transmethylation pathway that drives increased DNA methylation. Increased DNA methylation in turn is a pathological hallmark of epilepsy and causally linked to epilepsy development and progression. 3, 6 By reducing DNA methylation in the epileptic brain, ADK inhibitors can attenuate disease progression.
| Toxicology
The safety of adenosine has been demonstrated in several preclinical and clinical safety studies, which have been summarized in previous Eilat progress reports. 7, 10 Targeting of nuclear ADK-L is designed to correct a specific maladaptive response of the epileptogenic brain, that is, DNA hypermethylation caused by pathological overexpression of ADK, while minimizing adverse effects related to increased extracellular adenosine in healthy tissue and organs, such as suppression of cardiovascular functions and sedation. We have previously shown that adenosine augmentation therapy restores normal global DNA methylation levels in epileptic rats. 3 Mechanistically, an ADK-L inhibitor is expected to prevent DNA methylation specifically under conditions with high flux rates of methylation. For those reasons, the epigenetic effects of an ADK-L inhibitor are expected to be specific for pathological conditions associated with increased ADK-L (as occur in an epileptogenic focus), thereby avoiding widespread epigenetic side effects. By targeting the adenosine system, which is expected to restore normal global DNA methylation levels, epigenetic toxicities associated with anticancer drugs are not expected, because anticancer drugs have been designed to act as antimetabolites. For example, 5-azacytidine is integrated into DNA and acts as a DNA methylation inhibitor only after its integration. Most toxic effects of epigenetic anticancer drugs are based on direct interactions with DNA rather than blocking of DNA methylation per se. In contrast, adenosine as an endogenous metabolite of the transmethylation pathway is uniquely suited to restore equilibrium. Adverse effects resulting from systemic adenosine augmentation (eg, cardiovascular effects, sedation) are mediated by increased adenosine receptor activation through extracellular adenosine. Extracellular adenosine is largely under the control of cytoplasmic ADK-S. Hence, there is a rationale to screen for ADK-L-selective compounds to avoid adverse effects linked to ADK-S. Safety issues related to ADK-L blockade and its effects on the DNA methylome still need to be fully explored. However, the underlying biochemical mechanism (through mass action) favors the restoration of normal methylation homeostasis (ie, effects on pathological maladaptive DNA methylation) rather than affecting nonpathological methylation sites and directly counteracts DNA hypermethylation caused by pathological overexpression of ADK in epilepsy.
| Pharmacokinetics, metabolic profile, and drug interactions
The pharmacokinetics, metabolic profile, and drug interactions of adenosine have been summarized in previous reports. 7, 10 The pharmacokinetics, metabolism, and drug interaction profiles of MRS4203 and additional derivatives still need to be determined.
| Efficacy data, tolerability, and adverse effect profile
Preliminary data on the efficacy, tolerability, and adverse effect profile of adenosine and ADK inhibitors have been summarized in previous Eilat progress reports. 7, 10 Efficacy and tolerability data for MRS4203 and additional derivatives are not yet available.
| Planned studies
We plan to use an iterative cycle of compound development and testing to identify a clinical candidate compound based on our lead MRS4203. Efficacy, safety, and tolerability studies for those new compounds will be investigated in rodent models of epileptogenesis.
| BIS-001 (HUPERZINE A)
Stephen D. 
| Other pharmacological properties
BIS-001 shows potent analgesic/antinociceptive activity in animal models. 
| Mechanism of action
BIS-001 possesses a novel mechanism of action against seizures by increasing γ-aminobutyric acid (GABA) signaling through suppression of AChE activity. Stimulation of α7 and α4β2 nicotinic or muscarinic acetylcholine receptors facilitates GABA release through an accumulation of intracellular Ca 2+ . During periods of prolonged excitation, AChE expression is increased in an attempt to reduce acetylcholine-mediated excitatory signaling. 
| Toxicology
As reviewed by Zangara, 13 the oral median lethal dose for huperzine A in mice is 4.6 mg. Studies with 180-day treatment in dogs at a dose of 0.6 mg/kg intramuscularly and in rats at a dose of 1.5 mg/kg per os (po) showed no histopathological abnormalities. Additionally, no evidence of mutagenicity in rats or teratogenicity in mice or rabbits has been found.
| Pharmacokinetics and metabolic profile
Published data in humans suggest rapid absorption and wide distribution. 7,10 BIS-001 is about 42% bound to albumin.
Assessment of BIS-001ER in canines demonstrated an improved pharmacokinetic profile over the immediaterelease formulation. At a dose of 0.49 mg/kg, there was a delay in time to peak plasma concentration (t max ), from 1.25 hour for the immediate-release formulation to 4 hours for BIS-001ER (extended release), with an increase in apparent half-life from 5 to 8 hours. In addition, peak plasma concentrations (C max ) values were reduced by about 50%, from 12.7 ng/mL for the immediate-release formulation to 6 ng/mL for BIS-001ER.
A Chinese study of huperzine A metabolism in human microsomes suggested that metabolism via the cytochrome BIALER ET AL. P450 (CYP) pathway is not a major route of elimination. 14 In the same study, huperzine A (0.1 mg) was given orally to 14 elderly subjects and about 35% of the dose was found to be excreted unchanged in urine within 48 hours, suggesting that in humans, renal excretion is a major route of elimination.
| Drug interactions
Huperzine A, tested at concentrations of 0.2-100 ng/mL in human liver microsomes, showed negligible inhibition of CYP1A2, CYP2A6, CYP2C9, CYP2C19, CYP2D6, CYP2E1, and CYP3A4. 14 In the same study, incubation of human liver hepatocytes with huperzine A (2 and 20 ng/ mL) also had no influence on CYP1A2 and CYP3A4 activity. Based on these results, BIS-001 would not be expected to affect the metabolism of other AEDs.
| Efficacy data
There have been no studies to assess the therapeutic efficacy of BIS-001 in patients with seizure disorders.
| Tolerability and adverse effect profile
In 2012, Biscayne Neurotherapeutics completed a phase I investigator-sponsored clinical trial investigating the safety and tolerability of huperzine A in adult subjects with seizures refractory to current medications. Throughout the course of the study, moderate but unacceptable AEs were reported. Subjects 1 and 2 at a dose of 800 μg experienced nausea and emesis typical of a cholinergic drug, and withdrew from the study. The dose was lowered to 400 μg or 600 μg four times daily for the remaining subjects. The last six subjects completed the study but still experienced nausea, and in some cases vomiting, within the first 31 hours, most probably as a result of the rapid absorption of the immediate-release formulation. Following the initial nausea and vomiting episodes, and treatment with antiemetics, subjects stabilized and symptoms subsided. High serum peak levels of drug were associated with the nausea and vomiting, consistent with all other class members of AChE inhibitors. With the assistance of Drs. Terence O'Brien, Patrick Kwan, and Piero Perucca at the Royal Melbourne Hospital (Melbourne, Australia), Biscayne Neurotherapeutics completed a phase Ib investigator-sponsored clinical trial investigating the safety and tolerability of BIS-001ER in adult healthy volunteers. BIS-001ER showed a dramatic reduction in AEs compared with earlier experience with the immediate-release formulation. In the case of BIS-001ER, AEs were mild to moderate in nature and were transient without the need for prolonged treatment with an alternative medication to control side effects. The phase Ib study further demonstrated that doses twice as high as those predicted for significant seizure protection displayed stable plasma concentrations of BIS-001 using a b.i.d. dosing schedule. This study confirmed that the doses necessary for adequate seizure protection are attainable, while producing a favorable safety profile for continued clinical development.
| Planned studies
Biscayne Neurotherapeutics is initiating a proof-of-concept clinical trial testing the efficacy of BIS-001ER in subjects with focal impaired awareness seizures using in-patient video-electroencephalographic (EEG) monitoring. The study is scheduled to begin in the first quarter of 2018. Furthermore, Biscayne is planning to begin in the second quarter of 2018 a pilot study to assess the efficacy of BIS-001ER in adolescents and adults diagnosed with Dravet syndrome or Lennox-Gastaut syndrome. As described in a previous Eilat progress report, 7 2-deoxy-D-glucose exerts protective effects against secondary neurological damage and associated behavioral effects in the controlled cortical impact model of traumatic brain injury, both in Sprague-Dawley rats and in "perforant path kindling susceptible" (PPKS) rats. Following a controlled cortical impact, PPKS rats, a rodent strain with enhanced susceptibility to kindling progression, develop frequent focal and generalized spike-wave seizures (eg, every 1-5 minutes), with durations of~8-15 seconds. 18 Treatment with 2-deoxy-D-glucose (250 mg/kg/d by oral gavage) for 2 weeks after controlled cortical impact in this strain produced a~2-fold reduction in the emergence of posttraumatic seizures, with only three of 15 2-deoxy-D-glucosetreated PPKS rats developing seizures after controlled cortical impact compared with 16 of 32 saline-treated PPKS rats (P < 0.033, chi-square) during 6 months of video-EEG recording after injury. 18 As 2-deoxy-D-glucose was administered for only 2 weeks following injury, the observation of reduced emergence of posttraumatic seizures after initial remote injury as long as 6 months after injury cannot be ascribed to acute anticonvulsant actions, but reflects a neuroprotective, antiepileptic action that reduces the repeated unprovoked seizures at long intervals after traumatic brain injury that define posttraumatic epilepsy. The effects of 2-deoxy-D-glucose were dose-dependent, as eight of 15 PPKS rats treated with 50 mg/kg/d demonstrated frequent generalized spike-wave seizures as observed in saline-treated controls. 18 These results demonstrate that brief treatment with 2-deoxy-D-glucose after initial brain injury has the potential to modify the development of posttraumatic epilepsy.
| 2-DEOXY-D-GLUCOSE
| Mechanisms of action
As described in a previous Eilat progress report, 7 2-deoxy- ] o appears to be presynaptic, as indicated by reduction in the frequency but not the amplitude of miniature excitatory postsynaptic currents. 7 The chronic "disease-modifying" effects of 2-deoxy-D-glucose in the kindling experiments involve metabolic regulation of seizure-induced gene expression dependent on neuron restrictive silencing factor and carboxy-terminal binding protein. 
| Toxicology
Results of toxicology studies conducted with 2-deoxy-Dglucose are summarized in previous Eilat progress reports. 7, 10 In preclinical toxicology studies including three studies in rats and two studies in beagle dogs, 2-deoxy-Dglucose induced dose-dependent, reversible cardiac toxicity in rats consisting of cardiac myocyte vacuolation with features consistent with autophagy. The dose-dependent, cardiac myocyte vacuolation in rats is accompanied by increases in plasma N-terminal pro-brain natriuretic peptide compared to normal controls at the onset of vacuolation after 15 days of treatment. In a phase I study in cancer patients, 2-deoxy-D-glucose doses of 60 mg/kg/d resulted in dose-limiting toxicity consisting of grade 3 asymptomatic QTc prolongation in two of four patients. No grade 3 QTc prolongation was observed at doses of 45 mg/kg/d, which will likely influence dose selection in studies in patients with epilepsy. 
| Planned studies
Pending completion of preclinical studies, an initial clinical trial of 2-deoxy-D-glucose to evaluate safety and tolerability in patients with frequent, medically intractable seizures is anticipated. A phase II study with administration of 2-deoxy-D-glucose at low doses in combination with stimulation device therapy is also under consideration to exploit the activitydependent delivery of 2-deoxy-D-glucose into epileptic brain regions with increased energetic demands in response to seizures and stimulation. Potential therapeutic indications include Lennox-Gastaut syndrome and refractory frequent focal or generalized seizures, acute repetitive seizures (clusters), status epilepticus, combination with device therapies, and after initial mild and major traumatic brain injury to prevent adverse long-term sequelae including posttraumatic epilepsy, posttraumatic stress disorder, and chronic traumatic encephalopathy.
| FV-082
Malik Slassi
Trillium Therapeutics Inc., Toronto, Canada 21 was found to display broad-spectrum antiseizure activity and an excellent safety profile in preclinical testing, as previously described in the EILAT XIII progress report. 
| Pharmacology
The activity profiles of FV-082 in experimental models of seizures, epilepsy, and neuropathic pain have been reported previously. 7 The mechanism of action of FV-082 is considered to be multifaceted. Studies have suggested that the compound interacts with androgen receptors and human recombinant enzyme monoamine oxidase type B. The relationship between these observations and the antiseizure and analgesic effects of FV-082 remains unclear. In separate studies using whole-cell patch-clamp techniques, FV-082 was found to inhibit the voltage-gated Na + channel Nav1.8.
| Toxicology
Acute toxicity studies with FV-082 have been reported previously, 7 and only multiple-dose studies are summarized in this section. In a 28-day repeated-dose (0, 100, 200, 400, and 800 mg/kg/d po) toxicity study in male and female SpragueDawley rats, followed by a 14-day recovery period, FV-082 was generally well tolerated at doses up to 550 mg/kg/d. The 800 mg/kg/d cohort was reduced to 550 mg/kg/d after 6 days and maintained throughout the remaining 22 days of treatment due to observed weight loss. No other immediate adverse reactions were noted during or after each daily dose, and all animals survived the 28-day treatment. There was no appreciable indication of organ damage in gross pathology samples obtained on day 29 (day after final dose) and day 43 (last day of recovery). Effects on hematology, enzymes, electrolytes, metabolic parameters, and urinalysis were mild and transient, and likely attributable to variations in handling and altered feed intake. Evaluation of plasma FV-082 concentration profiles was conducted on day 1 and 28 of the 28-day toxicology study. The study on day 28 showed that C max and area under the plasma concentration versus time curve (AUC) values were higher in female rats compared to male rats, possibly related to lower body weight in female animals. C max and AUC 0-24 h values increased with increasing doses within the 100-550 mg/kg dose range. The oral absorption of FV-082 was prolonged, and the estimated mean residence time of FV-082 across all doses (7-14.6 hours) was considerably longer than would be expected based on the estimated plasma half-lives (1.5-11.6 hours), a finding consistent with a prolonged absorption phase. FV-082 had minimal accumulation in plasma following 28 days of dosing, when compared to day 1 plasma concentration profiles for each respective dosing cohort.
| Pharmacokinetics and drug interactions
The pharmacokinetic profile of FV-082 in mice, rats, and dogs has been summarized in a previous report. 7 Its potential for drug-drug interactions has been evaluated in in vitro studies using human liver microsomes enriched with CYP1A2, CYP2A6, CYP2B6, CYP2C9, CYP2C19, CYP2D6, CYP2E1, and CYP3A4 isozymes. In these studies, FV-082 did not exhibit significant inhibitory effects on any of the aforementioned isozymes when tested at concentrations up to 500 μmol/L.
| Planned studies
Ongoing studies are investigating the effect of chronic oral dosing on spontaneous seizures occurring after kainic acid-induced status epilepticus in rats. Investigational New Drug (IND)-enabling studies in nonhuman primates are planned, and a convenient cost-effective manufacturing process for FV-082 has been developed, allowing for multikilogram scale synthesis.
| FV-137
Malik Slassi Trillium Therapeutics Inc., Toronto, Canada FV-137 was also active in four kindling models, including the corneally kindled mouse, the amygdala kindled rat, the hippocampal kindled rat, and the lamotrigine-resistant amygdala kindled rat with ED 50 values of 70.4, 50.0, 49.4, and 32.6 mg/kg ip, respectively. FV-137 also demonstrated activity against hippocampal paroxysmal discharges in the post-kainic acid mouse model of pharmacoresistant mesial temporal lobe epilepsy, with an ED 50 of 125 mg/kg ip.
Lastly, FV-137 at a 100 μmol/L concentration demonstrated robust efficacy in an in vitro spontaneous electrographic bursting model of pharmacoresistance, that is, the combined medial entorhinal cortex-hippocampal slice preparation where brain slices are derived from kainic acid-induced status epilepticus in rats.
Collectively, the activity profile of FV-137 suggests that it could be useful for treating multiple seizure types, including generalized tonic-clonic seizures and pharmacoresistant seizures, at dose levels that confer a favorable safety margin. On the basis of its pharmacology, FV-137 is a promising candidate for clinical testing.
| Other pharmacological properties
FV-137 has been found to possess activity in the rat spinal nerve injury model and spinal nerve ligation model of neuropathic pain, at doses of 23 and 60 mg/kg ip, respectively. FV-137 (41 mg/kg ip) is also active in the mouse model of formalin-induced inflammatory pain.
| Mechanisms of action
In whole-cell patch-clamp studies, FV-137 inhibited P/Qtype Ca 2+ channels Cav2.1/β4/α2δ1 (IC 50 = 54.8 μmol/L) and Cav2.2/β3/α2δ1 (IC 50 = 48.7 μmol/L), and voltagegated Na + channels Nav1.6 and Nav1.7 (46% and 45% inhibition at 100 μmol/L, respectively). At concentrations up to 100 μmol/L, no inhibition was observed in other related ion channels (eg, Nav1.1, Nav1.5, Nav1.8, Kir2.1, Cav1.2, Cav3.2, HCN2, KCNQ2, and KCNQ3). At a concentration of 10 μmol/L, no significant effects of FV-137 were observed in a CEREP (Celle-Lévescault, France) broad profiling screen that included 90 known G protein-coupled receptors, ion channels, transporters, and enzyme targets.
| Toxicology data
Irwin and acute toxicity studies suggest that the maximum tolerated po dose of FV-137 is >500 mg/kg in both mice and rats. The protective index, defined as the ratio between the TD 50 for rat behavioral impairment (eg, rat rotarod test) and the median ED 50 in the MES test in the rat, was >22 (TD 50 > 500 mg/kg) following po administration. In a 5-day safety study in rats given FV-137 doses of 100 and 200 mg/kg po, there were no lesions present in liver samples examined from animals in either of the two test groups. In the same study, there was no evidence for hepatotoxicity as determined by measurement of blood liver enzymes, and no changes in other organs (brain and heart) relative to controls were observed. No functional hERG activity was observed at concentrations approaching 50 μmol/L.
| Preclinical pharmacokinetics
In preclinical pharmacokinetic studies, orally administered FV-137 was found to be well absorbed, with bioavailability values of 84% in rats and 95% in mice. Half-life values of FV-137 were 3.2 and 0.7 hours in rats and mice, respectively. In both rats and mice, exposure as measured by C max and AUC values was shown to be linearly related to dose after oral doses ranging from 20 to 200 mg/kg.
| Drug interactions
In in vitro studies, FV-137 did not inhibit major CYP isozymes (CYP2A6, CYP2B6, CYP2C9, CYP2C19, CYP2E1, CYP3A4) when tested at concentrations of up to 500 μmol/L, except for CYP1A2 and CYP2D6, for which IC 50 values were 19 and 156 μmol/L, respectively.
| Planned studies
Ongoing studies are being conducted in models of pharmacoresistant epilepsy, such as the rat model of spontaneous recurrent seizures following kainic acid-induced status epilepticus. A convenient and cost-effective manufacturing process for FV-137 has been developed, allowing for multikilogram scale synthesis. IND-enabling studies are being planned. 
| JNJ-40411813 AND POSITIVE
ALLOSTERIC MODULATORS OF GLUTAMATE METABOTROPIC RECEPTOR TYPE 2
| Introduction
Regulation of the release of glutamate may be an important mechanism for the modulation of glutamate signaling in epilepsy. The metabotropic glutamate receptor type 2 (mGlu2), located predominantly presynaptically and expressed in the frontal cortex and limbic structures related to epilepsy, serves to autoregulate glutamate release with a feedback mechanism that decreases glutamate release as excitatory activity increases. 23 This suggests that mGlu2 agonists and positive allosteric modulators (PAMs) would have antiseizure properties. The widely used AED levetiracetam orthosterically binds to the presynaptic vesicular release protein SV2A, which is associated with glutamate release. 24 Given the common presynaptic localization of their targets, modulators of mGlu2 could potentially interact with levetiracetam and vice versa.
Here, we summarize the data on the potential synergy between mGlu2 PAMs (using the clinical candidate JNJ-40411813 and preclinical tool compound JNJ-46356479) and levetiracetam. The results implicate a potential pharmacodynamic interaction between levetiracetam and mGlu2 PAMs resulting in synergistic seizure-protecting activity in the 6-Hz 44-mA mouse model and in the corneal kindling mouse model, without increasing adverse effects as measured by rotarod performance. Specifically, isobolographic analysis in the 6-Hz 44-mA model revealed a strong multifold seizure protection synergy between levetiracetam and mGlu2 PAMs. 25 This positive pharmacodynamic interaction might be especially useful in epilepsy, where increases in glutamate release and extracellular levels associated with increasing excitability in preseizure and active seizure states have been observed, and an mGlu2 PAM could readily downregulate glutamate release on an on-demand basis. A presynaptic pharmacodynamic interaction is implicated and supports the concept for rational polypharmacy in epilepsy treatment. In a portfolio of mGlu2 PAMs, the lead compound JNJ-40411813 (Addex ADX71149) is phase II ready and an optimized backup is phase I ready. A time-to-event proof-of-concept study for efficient and safe efficacy signal determination and dose ranging is considered to be an efficient approach to evaluate a signal of synergy and dose ranging.
| Pharmacology
| Activity profile in experimental seizure and epilepsy models
In the mouse corneal kindling model, tool compound mGlu2 PAMs are active in protecting against seizure expression and in reducing seizure severity in a dosedependent and mechanistically specific manner. JNJ-40411813
(
, a modestly potent mGlu2 PAM, 25, 26 was not active at 100 mg/kg sc in the corneal kindled mouse and was also inactive in the MES and sc PTZ models, with ED 50 estimates > 100 mg/kg when administered sc. JNJ-40411813, however, was active in both the 32-mA and 44-mA 6-Hz models in mice. 25 At doses of 2.5-30 mg/ kg sc, 100% of animals were protected at the maximal dose in the 32-mA 6-Hz model (n = An isobolographic analysis was performed using the 44-mA 6-Hz model. An ineffective sc dose of JNJ-40411813 was used in combination with varying sc doses of levetiracetam, with a high level of protective activity (>75% protection) being observed at 25 mg/kg and higher doses of levetiracetam. The ED 50 for levetiracetam, when used in combination with JNJ-40411813, was 9.6 mg/kg (95% CI = 1.7-21.9), which corresponds to a >35-fold increase in levetiracetam potency compared to levetiracetam administered alone. The activity of varying doses of JNJ-40411813 was also evaluated using the ED 50 dose of levetiracetam in the 44-mA 6-Hz model. At this fixed levetiracetam dose, levetiracetam shifted the potency of JNJ-40411813 leftward 14-fold, resulting in an ED 50 of 1.3 mg/kg (95% CI = 0.3-2.2). The synergy observed in this study was not the result of a pharmacokinetic interaction, that is, plasma levels of JNJ-40411813 or levetiracetam were not significantly different compared to plasma levels observed when compounds were administered alone or in combination.
The data with other selective mGlu2 PAMs (preclinical tool compounds JNJ-46356479 and JNJ-42153605) and agonists (LY404039) suggested potency of the mGlu2 PAM or agonist as the most significant contributor of synergy. 25, 26 The synergy in the 6-Hz 44-mA model is observed exclusively with AEDs that bind SV2A and not with AEDs that have other mechanisms of action such as lamotrigine, valproic acid, 26 carbamazepine, and diazepam (Janssen Research & Development, data on file). Studies of levetiracetam with selective mGlu2 PAM tool compounds in corneal kindled mice confirm a pharmacodynamic interaction in both percentage of animals protected and marked reductions in seizure severity scores. 26 In summary, JNJ-40411813 is potently effective in the 6-Hz mouse assay at both 32-and 44-mA pharmacoresistant stimulus intensities. Furthermore, whereas levetiracetam loses potency and efficacy in the 44-mA test, efficacy and potency are reestablished at much lower dosages when levetiracetam is coadministered with a subprotective dose of JNJ-40411813 or other mGlu2 PAMs. A similar synergy was observed when a subprotective dose of levetiracetam was evaluated in combination with mGlu2 PAMs. As a pharmacokinetic interaction was not observed, the activity observed in the combination studies suggests a positive pharmacodynamic interaction. A similar pharmacodynamic interaction was observed between mGlu2 PAMs and levetiracetam in the rat amygdala kindling model, that is, JNJ-40411813 significantly enhanced the protective effects of levetiracetam against seizure severity score and behavioral seizure duration in this model. The positive pharmacodynamic effect seems to be specific to levetiracetam, as combinations with diazepam and carbamazepine showed only a modest pharmacodynamic effect. Finally, these observations implicate a possible presynaptic pharmacodynamic interaction and support a rational polypharmacy concept for the treatment of patients with epilepsy.
| Other pharmacological properties
At a dose of 3 mg/kg po, JNJ-40411813 dose-dependently suppressed rapid eye movement sleep and promoted and consolidated deep sleep in rats. 27 Orthosteric agonists at the mGlu2 receptor have shown mixed results in clinical studies of schizophrenia. In an evaluation of potential antipsychotic properties, JNJ-40411813 inhibited spontaneous locomotion and phencyclidine-, scopolamine-, but not D-amphetamine-induced hyperlocomotion in rodent models. 
| Mechanism of action
JNJ-40411813 binds to an allosteric modulator site independent of the agonist binding site on the mGlu2 receptor. In vitro functional experiments using cell lines overexpressing the human mGlu2 receptor showed that JNJ-40411813 increased both the activity and the potency of glutamate on the mGlu2 presynaptic receptors. JNJ-40411813 allosterically potentiated glutamate-induced mGlu2 activation by 273 ± 32%, with a median effective concentration (EC 50 
| Toxicology
JNJ-40411813 has been evaluated in several safety pharmacology studies, genotoxicity studies, male and female fertility studies in rats, embryofetal developmental toxicity studies in rats and rabbits, an in vitro phototoxicity study, and a local lymph node assay. Multiple-dose toxicology studies have been conducted in rats and dogs up to 3 months with no significant toxicology findings, although absorption characteristics in these animals precluded testing at very high dosages. Other repeated-dose studies have been done in rats and dogs in which alternative administration routes and/or regimens were analyzed to increase the exposure of JNJ-40411813. The preclinical package has been used to support clinical studies up to 3 months of dosing at a dose of 150 mg b.i.d.
| Pharmacokinetics and drug interactions
Within the 50-225 mg dose range, JNJ-40411813 has an expected oral bioavailability in humans of 20%-50%, as estimated using GastroPlus modeling. JNJ-40411813 is metabolized through CYP3A4 and is a mild mechanism-based inhibitor of CYP3A4. In single-dose studies up to 1000 mg, the half-life of JNJ-40411813 ranged from 10 to 27 hours. In repeated-dose studies with doses up to 225 mg b.i.d., the accumulation ratio ranged from 2.6 to 3.8, and mean steadystate half-life increased from approximately 15 hours for a single dose to approximately 24 hours when given b.i.d. over 7 days using the 100 mg nanosuspension formulation.
A clinical drug interaction study using a single dose of JNJ-40411813 coadministered with a strong CYP3A4 inhibitor (ketoconazole) resulted in a 1.4-fold increase in C max and a sevenfold increase in AUC. A circulating metabolite has been identified as M45 and has an ED 50 of 421 nmol/L in the human mGlu2 Chinese hamster ovary GTPgammaS assay (Janssen Research & Development, data on file).
| Efficacy and tolerability
To date, nine phase I clinical studies have been completed, including a total of 345 healthy subjects, 286 of whom received JNJ-40411813 across a dose range of 5-1000 mg (single-dose studies) or 50-225 mg b.i.d. (multiple-dose studies). The phase I studies revealed that JNJ-40411813 was safe and generally well tolerated.
JNJ-40411813 has been studied in an exploratory add-on and monotherapy study in 100 patients with chronic schizophrenia, and results indicated a possible benefit in patients with prominent negative symptoms (Janssen Research & Development, data on file). An exploratory study with doses up to 150 mg b.i.d. in 121 patients with anxious depression did not provide data to warrant further development in this indication. 29 Dizziness was the most noteworthy AE at the highest dose, and dose titration seemed to reduce its incidence. Overall, JNJ-40411813 appeared to be safe and well tolerated.
| Planned studies
Although synergy observed in isobolographic studies in animal models may not reflect synergy for drug combinations in human epilepsy, clinical studies are warranted. Potential plans include a randomized, double-blind, placebo-controlled phase IIa proof-of-concept study of adjunctive treatment with JNJ-40411813 in patients with focal seizures and suboptimal response to levetiracetam, using a time-to-event trial design. The model leverages the time between events to reduce not only exposure to placebo but also the prerandomization baseline period needed, without loss of power compared to traditional parallel-group studies. Using an adaptive design, the approach allows for rapid signal finding (both presence of efficacy and strength of efficacy) and for dose ranging, including extension data that provide some longer-term efficacy information using traditional variables (seizure freedom and 50% responder rates but not median monthly seizure frequency change). The objectives of the study were to evaluate efficacy, safety, and tolerability of up to three doses of adjunctive JNJ-40411813 compared to placebo and to evaluate the exposure-response relationship using an estimate of individual subject exposures from population pharmacokinetic analysis and the end point of time to baseline seizure count.
| Introduction
The α-amino-3-hydroxyl-5-methyl-4-isoxazolepropionic acid (AMPA) subtype of ionotropic glutamate receptors mediates the majority of fast synaptic transmission within the mammalian brain. 30 The ubiquitous expression of the primary subunits of AMPA receptors and the lack of pharmacological selectivity among them preclude regional or neuronal subtype specificity. In vivo, AMPA receptors are associated with a variety of accessory proteins, such as transmembrane AMPA receptor regulatory protein γ8 (TARP-γ8).
TARP
proteins have multiple effects on AMPA receptors, such as increasing their surface expression and increasing AMPAactivated currents upon activation, while altering the channel kinetics (slower desensitization and deactivation).
32
Using high-throughput screening, we discovered compounds that selectively modulate AMPA receptors containing TARP-γ8. Subsequent medicinal chemistry efforts were used to improve potency and pharmacokinetics of the hits. Assays were developed to measure target occupancy and functional effects of the compounds in vivo.
JNJ-55511118 is a highly potent, selective negative modulator of AMPA receptors containing TARP-γ8 (AMPA receptors γ8). 33 It is a brain-penetrant agent that can be given orally and is an excellent preclinical tool compound to investigate the potential anticonvulsant properties of selective AMPA receptor γ8-negative modulators. Improved analogs of JNJ-55511118 have been discovered, and the lead compound JNJ-AMPA is progressing into clinical development.
| Pharmacology
| Activity profile in experimental
seizure and epilepsy models JNJ-55511118 shows strong protection in the corneal kindling and PTZ models in mice and in the amygdala kindling model in rats. The compound also shows partial protection in the 6-Hz and MES tests in mice.
In the mouse corneal kindling model, JNJ-55511118 reduces the severity of seizures with an ED 50 of 3.7 mg/kg po without any motor impairment as measured by the rotarod test. Near complete seizure protection was noted at and above 5 mg/kg po, with 80% seizure protection corresponding to approximately 70% receptor occupancy as measured by ex vivo autoradiography.
JNJ-55511118 was also tested in the amygdala kindling model in rats. This compound protected 11 of 12 rats from seizure (2 hours after dose, 10 mg/kg po), compared with 1 of 12 rats protected with vehicle alone. The afterdischarge duration was significantly reduced by JNJ-55511118 at the same dose.
JNJ-55511118 showed partial protection in the 6-Hz models. At doses of 10-40 mg/kg po, projected to give target occupancies of 80% or greater, 12 of 32 (37.5%) animals were protected in the 6-Hz 32-mA model, and 11 of 40 (27.5%) were protected in the 6-Hz 44-mA model. This compound was also tested in the MES model; at 40 mg/kg po, 50% of the animals showed seizure protection.
The preclinical profile of JNJ-55511118 is representative for various AMPA receptor γ8-negative modulators, including JNJ-AMPA, the clinical development candidate. JNJ-AMPA reduces the severity of seizures with an ED 50 of 0.074 mg/kg po in the mouse corneal kindling model.
| Other pharmacological properties
Oral administration of JNJ-55511118 (1-10 mg/kg) elicited a clear dose-dependent decrease in EEG activity during the wake state in all frequency bands > 4 Hz in rats. This reduction in EEG power was accompanied by a significant increase in locomotor activity for approximately 1 hour after dose.
AMPA receptors have been associated with regulation of hippocampal plasticity and short-term memory mechanisms important for performance on spatial and working memory tasks. 30 JNJ-55511118 (dose range from 0.63 to 10 mg/kg po) was tested in the V-maze, Morris Water Maze, and delayed nonmatch to position model. Only mild cognitive impairment was noted. Overall behavior of animals dosed with JNJ-55511118 appeared largely normal, with only transient hyperlocomotion immediately after dosing and upon transfer into a novel environment.
| Mechanism of action
Until recently, no AMPA receptor inhibitors have been found to have selectivity among the AMPA receptor subtypes, or to exhibit regional specificity. Instead, targeting TARPs that do show brain region-specific expression can provide AMPA receptor modulators with an improved therapeutic window. The expression pattern of TARP γ8 is particularly attractive, as it is the predominant TARP in hippocampus, with very little expression in hindbrain and midbrain. 34 Negative modulation of AMPA receptor γ8 offers the possibility of selectively reducing excitatory transmission within brain circuits associated with epilepsy. Both Lilly/Cerecor and Janssen Research & Development have disclosed compounds targeting AMPA receptor γ8.
35,36
JNJ-55511118 is a selective negative modulator of AMPA receptor γ8, with approximately 1000× selectivity versus AMPA receptors containing other TARPs (eg, γ2, γ4) or versus TARP-less receptors. In in vitro electrophysiological studies using hippocampal neurons, JNJ-55511118 at a 1 μmol/L concentration only partially reduces AMPA receptor peak responses.
| Toxicology
JNJ-55511118 was evaluated in non-good laboratory practice (non-GLP) short-term toxicology studies in rat and dog. In a rat 14-day tolerability study, the compound showed dose-dependent hepatocellular toxicity at 20 and 60 mg/kg/d, which prohibits further development, but JNJ-55511118 remains an excellent compound for use as a tool in pharmacological studies.
The clinical candidate JNJ-AMPA has been evaluated in GLP toxicology studies in rats and dogs. After 1 month of treatment (5-200 mg/kg in rats and 5-220 mg/kg in dogs), the compound was well tolerated in both species and large safety margins were obtained.
| Planned studies
JNJ-55511118 is a suitable tool compound to study the in vitro and in vivo pharmacology of AMPA receptor γ8-negative modulators.
JNJ-AMPA is progressing to phase I single and multiple ascending dose studies, after which the compound can be evaluated in a clinical proof-of-concept study in epilepsy.
In addition, Janssen Research & Development has developed an AMPA receptor γ8 positron emission tomography (PET) ligand, [ 18 F]JNJ-64511070. This PET ligand has been successfully used in monkey PET studies to define target engagement of AMPA receptor γ8-negative modulators such as JNJ-AMPA. Clinical validation of the PET ligand is ongoing, and subsequently a clinical displacement study can be performed with JNJ-AMPA to enable dose selection for the clinical proof-of-concept study in epilepsy.
| Conclusion
Modulation of AMPA receptor signaling using a selective TARP γ8 mechanism has two distinct advantages: the expression of TARP γ8 within the brain indicates that the drug will have its largest effect within the hippocampus, while avoiding direct inhibitory effects on brain regions involved in motor coordination and wakefulness. Second, the compounds negatively modulate but do not completely inhibit AMPA receptor signaling. It still needs to be proven whether this will result in effective anticonvulsant therapeutics with an improved therapeutic margin. JNJ-AMPA has the potential to provide clinical proof of concept in epilepsy patients. 
| KETONE-ENHANCED ANTIEPILEPTIC DRUGS
| Introduction and rationale for development
The ketogenic diet is considered an effective therapy for children and adults with refractory epilepsy, but its use is limited due to its unpalatable nature and potential cardiovascular risks. 37 The ketogenic diet produces antiseizure activity in some animal models of epilepsy, presumably through the action of ketone bodies. 38, 39 Ketones known to be produced in the body, such as acetone, display anticonvulsant activity similar to that of the ketogenic diet in rodent seizure models, including the MES, PTZ, and 6-Hz tests, albeit at doses that also cause ataxia (Andrew J, unpublished data). 40 Acetone and other ketones are not likely to be useful as stand-alone AEDs, given their short half-life. The ketone plasma levels often do not correlate with anticonvulsant activity. 41 Local brain ketone levels may be a more accurate way of measuring anticonvulsant activity. 42 However, acetone when administered in combination with certain AEDs such as valproic acid and carbamazepine showed some additive or possibly synergistic effects, resulting in a different anticonvulsant activity profile compared to the parent AED. 43 Ketogen has designed several series of "multivalent" new chemical entities (NCEs) that incorporate effective AED components directly linked to one of several ketone-generating moieties. The AED acts as an active carrier to bring the ketone-generating group (KGG) into the CNS and provides a unique way to reduce side effects and body load of ketones, while improving tolerability and the overall benefit-risk ratio. The choice of AED and KGG can markedly affect the response.
| Pharmacology
| Activity profile in experimental models of seizures
Conjugating AEDs with a KGG resulted in a clear change in anticonvulsant activity profile. In some models where both original moieties were inactive, the conjugate produced a clearly active compound, differentiating the NCE from the individual constituents alone. For example, Figure 1 illustrates the antiseizure activity in the 6-Hz 44-mA mouse model, where both single agents are inactive but the conjugate (KG-110) given at the same dose (mg/kg) is clearly active. At a molar level, KG-110 contains about half of the amount that was tested in groups dosed with single agents. In all the figures included in the present report, the AED motif is levetiracetam and the KGG can vary. As shown in Figure 2 , these transforming effects are seen across a range of mouse seizure models, and this activity has been confirmed in independent laboratories using the ETSP at the National Institute of Neurological Disorders and Stroke. Figure 2 illustrates the response of KG-131, a KGG conjugate of AED1, in the MES test, the PTZ test, and the 6-Hz 44-mA mouse model. In these experiments, KG-131 (red bars) substantially reduced the incidence of seizures by 70%-85%, whereas the parent AED (AED1, blue bars) was inactive or poorly active at equimolar dose levels. These data were generated both internally and through the ETSP at the National Institute of Neurological Disorders and Stroke. AED1 is levetiracetam.
The choice of AED and KGG can dramatically affect the response. Not all AEDs show interaction/synergy with ketones, and not all KGGs produce the same degrees of potentiation. KG-110, KG-130, and KG-131 all contain the same parent AED motif (AED1) with different KGGs, which produce different efficacy profiles across animal models. Figure 3 shows the activity of the same equimolar dose of AED1 in the MES model (45-mA constant current; n = 10 animals/group) given alone and attached to distinct KGGs (KGG1, KKG2, KGG3). The type of KGG used influences the activity of the conjugate. The chemistry, namely the location at which the KGG is bound to the AED, is a key factor, as this can determine whether a compound is active or inactive using the same components. Interestingly, the efficacy of these compounds is evident in normally fed animals and occurs within 15-30 minutes after ip dosing. Moreover, the anticonvulsant effects do not necessarily correlate with plasma markers of ketosis such as β-hydroxybutyrate. Full pharmacokinetic and metabolic studies for all molecules have not been completed, but the compounds are found in plasma and brain both as conjugate/prodrug and individual constituents. KG-110 for example has a brain/plasma ratio of >15.
| Mechanism of action
The mechanism of action of the ketogenic diet is believed to result from increased metabolism of fat with concomitant increase in the production of ketones such as acetone, acetoacetate, and β-hydroxybutyrate. The precise site of action of ketones is unknown.
The ability of ketones to enhance the activity of certain anticonvulsants 43 is difficult to predict; different sodium channel blockers, calcium channel blockers, and GABAergic AEDs can show no interaction or a positive interaction. Preliminary data for KG-131 shows anticonvulsant activity within 15-30 minutes after po dosing in normally fed animals, suggesting that the activity is independent of any significant shift in metabolism, but there is a more direct CNS effect.
| Toxicology data
Preliminary 14-day toxicology studies with KG-110 using rats and dogs have suggested that there is no change in the observed toxicology with respect to the original constituents. Further studies are planned or in progress.
| Planned studies
Full pharmacokinetic and toxicology studies are planned with KG-131 with the aim of filing an IND and entering clinical trials. In recent years, much research has concentrated on epileptic disorders such as Dravet and Lennox-Gastaut syndromes. Other disorders, such as Glut-1 deficiency and Doose syndrome, have been neglected. Several of these disorders are often drug-refractory, but show some response to the ketogenic diet, 44, 45 suggesting that they are ketone sensitive and could serve as a focused and enriched population for testing the efficacy of these ketone-enhanced NCEs. In summary, novel compounds produced by linking an AED to a KGG produce an anticonvulsant profile distinct and differentiated from the parent AEDs and KGGs alone. Development plans include the testing of these compounds in pediatric populations that are refractory to current treatments but appear to be sensitive to ketogenic diet therapies This approach may provide a way to reduce the strictures of the ketogenic diet while improving therapeutic responsiveness. 
| OV329
| Introduction and rationale for development
Presynaptic release of GABA results in hyperpolarization of postsynaptic neuronal membrane potentials and a dampening of neuronal activity. Inhibition of GABA catabolism by vigabatrin through inactivation of GABA transaminase (GABA-T) has proven to be effective in selected forms of epilepsy, although progressive and irreversible visual loss in a substantial proportion of vigabatrin-treated individuals has limited the use of this compound and diminished interest in GABA-T as a target. 46 As a new inactivator of GABA-T with increased potency and the potential for reduced risk of retinal impairment compared to vigabatrin, OV329 is being developed as an adjunctive oral therapy for treatment of pharmacoresistant epilepsies.
| Pharmacology
| Activity profile in experimental seizure models
To evaluate OV329 as a potential treatment for infantile spasms, we investigated its effects on N-methyl-D-aspartate (NMDA)-induced seizures and motor deficits in mice. These studies determined that juvenile mice pretreated with a single dose of OV329 (≥0.01 mg/kg ip) 30 minutes ahead of a proconvulsant dose of NMDA (15 mg/kg ip) showed a significant reduction in seizure severity relative to vehicletreated animals (P < 0.001). Importantly, the significant NMDA-induced coordination deficits seen at 7 days in an adrenocorticotropic hormone-treated positive control group were not observed in mice treated once with OV329.
| Other pharmacologic properties
In vitro studies demonstrate time-and concentration-dependent inhibition of GABA-T, with inhibitory activity more than two orders of magnitude greater than vigabatrin (IC 50 = 0.28 and 58.5 μmol/L, respectively). Reduced ornithine transaminase activity was also observed in vitro, although this was 44-fold less relative to GABA-T. 47 Separate from this, no appreciable binding of OV329 to any of the 176 targets included in the Cerep Spectrum Screen was observed at 3 μmol/L. Consistent with findings for vigabatrin, a single dose of OV329 (0.1 mg/kg ip) blocked cocaine-induced striatal dopamine release and hippocampal glucose activity in freely moving rats, providing in vivo evidence for target engagement.
| Mechanism of action
Through inactivation of GABA-T, the enzyme responsible for catabolism of GABA to succinic semialdehyde, OV329 increases GABA transmission and inhibits neuronal activity. 47 
| Toxicology
No evidence of genetic toxicity or hERG channel activity was identified in vitro. In adult mice, an acute no-observedadverse-effect level (NOAEL) of 6 mg/kg po, a dose 600-fold greater than the lowest effective dose tested in the infantile spasms mouse model, was determined by evaluating behavioral neurotoxicity in naive animals. Administration of OV329 at 1 mg/kg/d po for 45 days in a separate cohort showed the compound to be well tolerated, with no reduction in body weight gain relative to control, no gross behavioral deficits, and no impact on retinal function as measured by electroretinogram (ie, retinal B-wave amplitudes). These findings stand in contrast to those from a head-to-head comparison with vigabatrin, where a dose with considerably less GABA-T inhibitory activity resulted in a marked reduction in weight and reductions in retinal B-wave amplitudes. The reason for the retinal toxicity observed in mice after administration of vigabatrin not being observed after administration of OV329 remains unknown. Based on these findings, however, it is clear that the inhibition of GABA-T is not necessarily associated with vigabatrinlike retinal toxicity.
| Pharmacokinetic and metabolic profile
Because OV329 inactivates GABA-T irreversibly, its duration of action is hypothesized to be dependent on the rate of enzyme resynthesis rather than the rate of elimination of the drug from the systemic circulation. No metabolism of OV329 was observed over a 90-minute incubation in human liver microsomes. Protein binding in human plasma was found to be 27%.
| Drug interactions
OV329 did not inhibit or induce CYP1A, CYP2B6, CYP2C8, CYP2C9, CYP2C19, CYP2D6, and CYP3A at 10 μmol/L in a non-GLP assay.
| Efficacy, tolerability, and adverse effect profile
No human studies have been initiated with OV329. INDenabling studies are in progress. that an orally active drug should have no more than one violation of the following criteria: (1) molecular weight < 500 Da, (2) log P (octanol-water partition coefficient) < 5, (3) <5 hydrogen bond donors, and (4) <10 hydrogen bond acceptors. 48 
| OXYNYTONES
| Pharmacology
| Lead identification studies and mechanism of action
Initial lead identification studies utilized voltage-sensitive dye imaging to examine the ability of candidates to dampen in vitro neuronal circuit activation in brain slices from rats. This technique follows the altered fluorescence of dye, which increases and decreases according to membrane potential. Evaluation of the NCEs focused on the suppression of activity in the piriform cortex, a region of the brain demonstrated to support epileptic seizures. Activation of this regional circuit was accomplished by stimulation of the lateral olfactory tract. In initial screening, some compounds had significantly more activity suppressing circuit excitation when the slice was driven at higher stimulation frequencies (60 Hz) with only marginal or no effects at lower rates (20 Hz) of simulation. The assumption was made that significant effects on low-frequency brain activity would be an undesirable pharmacological property, potentially having off-target effects on nonseizure states. Several NCEs were identified that demonstrated this frequency discrimination.
The lead compounds TD561 and TD562 at concentrations of either 50 or 200 nmol/L were tested for suppression of excitation elicited at 60 Hz versus 20 Hz. Significant attenuation by almost 50% was observed at 60 Hz, with notably less effect (0%-15%) at 20 Hz. Excitation of the pyramidal cell layer was compared under control conditions and in the presence of the NCEs. Figure 4 shows a representative field view of a screening result for a positive "hit" to a 60-Hz stimulation train for 1 second. Figure 5 shows a representative screening of a panel of NCEs evaluated by the same methodology. Of note, compounds preferentially dampened excitatory neuronal activity versus enhancing inhibitory neuronal activity within the circuit.
Although a number of compounds met the selection criteria, TD561 and TD562 were initially chosen for further evaluation in cultured embryonic cortical neurons (>14 days in vitro) based on the findings that at 50 nmol/L both reduced circuit activation by about 50% at 60 Hz but had less activity (0%-15%) in 20-Hz pulse trains. Voltage clamp patch recordings were conducted to investigate their mechanism of action. TD561 and TD562 had little or no activity on synaptic activity. The characteristic spontaneous low-frequency bursting activity that occurs in these cultures was unaffected by either. Next, the activation or deactivation kinetics of voltage-gated sodium and potassium currents was examined by voltage clamp. Little or no effect on sodium currents was seen at low rates of stimulation, but at shorter latencies these NCEs slowed recovery from fast channel inactivation. However, there was no increase in resting inactivation and recovery was complete in about 50-70 milliseconds (−60 mV holding potential; Figure 6 ).
Concentration-response curves were constructed by assessing the activity of TD561 and TD562 to suppress currents administered 16 milliseconds (roughly equivalent to a 60-Hz firing rate) after the control pulse. In contrast to the relative insensitivity of these compounds to low-frequency pacing of the cells (0.2 Hz), TD 561 and TD562 significantly attenuated recovery at short latencies with high potency (IC 50 ≅ 50 pmol/L). Figure 7 shows their marked shift in potency based upon frequency of sodium channel depolarization. The compounds seem to preferentially interact with the inactivated state, as they do not suppress sodium currents until very high concentrations are employed. The calculated IC 50 values suggest a 1000-fold selectivity over the inactivated state versus the resting state.
Moreover, concentrations that demonstrate attenuation of sodium channel activity had no effect on potassium currents. Only at very high concentrations (eg, 100 μmol/L) 2000-fold IC 50 were potassium currents modestly enhanced. In separate assays for effects on hERG channel activity, <20% inhibition was observed at 100 μmol/L TD561 or TD562. Although effects on voltage-gated calcium channel activity have not yet been investigated, no effect was observed on the spontaneous beating of cardiomyocytes in culture, suggesting no effects on calcium oscillations in these cells.
Overall, available data indicate that voltage-gated sodium channels are the validated target for the lead NCEs. In support of this, in an "off-target" screen of 44 ion channels and other CNS relevant G protein-coupled receptors and transporters (Eurofins/Cerep Panlabs, Celle-Lévescault, France), TD562 in particular showed no competitive inhibition at doses of 10 μmol/L. From the above studies, especially those related to the modulatory properties of TD561 and TD562 on voltage-gated sodium channels and other independently conducted studies with recombinant cells containing individual alpha (Nav 1.1, 1.2, 1.5, 1.6, and 1.7) subunits (data not shown), these molecules do not appear to block the channel pore (alpha subunit), enhance slow inactivation kinetics, or alter prolonged (second) depolarization/slow recovery kinetics. It may be that the electrophysiological properties of TD561 and TD562 reflect those attributed to the modulatory interactions of the known beta subunits associated with alpha subunits in the voltage-gated sodium channel complex. Studies are ongoing to investigate the hypothesis that molecules in this class either bind to beta subunits or effectively interfere with normal alpha-beta subunit interaction upon depolarization to alter the transition between channel state changes. As such, these molecules represent a new class of antiseizure compounds.
| Activity in experimental models of seizures and epilepsy
TD561 and TD562 were investigated in the rat amygdala kindling and the mouse 32-mA 6-Hz models. Both compounds suppressed the afterdischarge and prevented stage 5 kindled seizures with a single dose of 20 mg/kg po measured 3 hours postdose (Figure 8) . TD561 decreased the amygdala afterdischarge duration in a dose-dependent manner from each of the control stimulation durations, typically 36-42 seconds (5 mg/kg: 57.5%; 20 mg/kg: 85.6%; n = 5-6), and to a greater extent than an equivalent dose of levetiracetam (20 mg/kg: 17.1%; n = 9). In general, these compounds produce a twofold or greater increase in the threshold current required to achieve a stage 5 seizure with an afterdischarge duration comparable to control. However, TD561 was only effective at suppressing 6-Hz seizures at high doses (300 mg/kg, data not shown).
Further experiments were conducted to investigate potential effects on the development of amygdala kindling. TD561 (20 mg/kg po) was administered once daily (q.d.) 3 hours prior to stimulation during the kindling process. Animals were examined 3 hours postdose by amygdala stimulation with currents ranging from 100 to 700 μA. TD561 was found to prevent both the development of stage 5 seizures and the reduction in the afterdischarge threshold current required to elicit stage 5 seizures. The prevention by TD561 was additionally manifested in that the kindling process was extended to 20 days by the drug, well beyond normal kindling development time (10-12 days for rats not receiving drug). Furthermore, rats treated with TD561 during the kindling procedure did not reach stage 5 seizures. Animals were then taken off TD561 for 5 days, and kindling was reinitiated. Animals were then able to achieve stage 5 seizures, indicating proper prior placement and stimulation of the amygdala.
Two novel approaches are being used to further examine the utility of lead candidate NCEs for the treatment of epilepsy. The first involves the use of freshly resected human brain tissue from pharmacoresistant patients undergoing temporal lobe surgery. Slices from these tissues were immediately prepared in the same manner as those obtained TD561 at 10 nmol/L reduces the amplitude of the sodium current at 16 milliseconds by about 50% while having no effect on resting state currents (left panel). The complete dose-response relationships for suppression of the 16-millisecond test pulse states and resting states for TD561 and TD562 indicate the marked preference in potency for the fast activation/inactivation state (right panel) [Color figure can be viewed at wile yonlinelibrary.com] from rats for voltage-sensitive dye imaging recordings. In these preparations, TD561 suppressed ex vivo neuronal circuit excitation by approximately 45% (n = 6 patients; 13-22 slices) in a concentration-dependent manner up to 200 nmol/L. In contrast, carbamazepine was relatively ineffective (<15% reduction in neuronal circuit excitation) at concentrations 1000-fold greater (50 μmol/L). Thus, these tissues appear to reiterate the drug-resistant profile ex vivo and show evidence for the potential utility of this family of NCEs for the treatment of pharmacoresistant epilepsy.
The second approach involves testing the ability of lead NCEs in suppressing epileptiform activity in the amygdala in an established rat model of moderate brain injury using controlled cortical impact. 50, 51 Because stress and anxiety (eg, posttraumatic stress disorder) have been reported to increase the risk of posttraumatic seizures and posttraumatic epilepsy, 52 experiments in the rat controlled cortical impact model have been expanded to include acute application of a nonpainful "stressor" to rats after sufficient recovery from traumatic brain injury. Under these conditions, rats reproducibly exhibit stage 2-3 seizures characterized by electrical activity over a wide range of frequencies up to 500 Hz. Of importance, high-frequency oscillations in excess of 250 Hz, so-called "fast ripples," are believed to be pathophysiologic precursors to the development of epileptic foci. 53 In the absence of TD561, there is a robust stress-induced seizure response and evidence of high-power oscillations in the frequency spectrogram in the fast ripple range (250-500 Hz). After a single oral dose of 20 mg/kg po TD561 3 hours before, stress-induced seizures were suppressed and broad frequency epileptiform activity in the amygdala was attenuated. More importantly, fast ripples, which are thought to be epileptogenic, were nearly completely blocked. In contrast, the administration of phenytoin in this model had no effect or exacerbated fast ripples and seizure activity. These data suggest that the TD561 class may be useful in the suppression of the electrical activity that is believed to enhance the progression of epilepsy.
| Toxicology
No lethality was observed in CD-1 mice at doses of TD561 up to 1 g/kg ip. Only a small reduction in body temperature was noted at this highest dose, which recovered within 24 hours. In addition, no behavioural effects (sedation and righting reflex) were observed at 300, 600, and 1000 mg/kg ip over the 24 hours after the dose evaluation period. Given the rapid in vivo conversion of TD561 to TD6562, the data reflect the overall safety of the latter. Kindled rats treated with doses ranging from 5 to 100 mg mg/kg TD561 for 25-30 days were examined for behavioural abnormalities and tissue histopathology by Dr. Rudi Meuller at the University of Ottawa. No behavioural defects (lethargy, sedation, eating, drinking, etc) were observed. There was no evidence of any histopathology in tissues examined including heart, kidney, and liver.
In addition, an Ames test for both Salmonella strains TA98 and TA100 was negative for TD561 and TD562 at concentrations up to 10 μg/well (≅20 μg/mL top agar layer). Maximum inhibitory doses for either strain for TD561 and TD562 were >1000-fold greater than that of ciprofloxacin 0.125-0.250 μg/mL.
| Pharmacokinetic and metabolic profile
In studies with rats and mice, both TD561 and TD562 have shown an oral bioavailability of approximately 95%. Approximately 73% of TD562 is bound to human plasma proteins. TD561, an ester of TD562, is rapidly converted in both rat and human plasma, liver microsomes, and hepatocytes to the more stable TD562 by hydrolysis. This conversion and the in vivo presence of TD562 have been confirmed in preliminary pharmacokinetic tests in rats. TD562 exhibited a half-life of~3 hours after a 3-mg/kg iv dose of TD561 and~5 hour after a 10-mg/kg po dose of TD561, and no other metabolites were detected. Maximum brain concentrations were detected by 30 minutes after a 10-mg/kg dose po of TD561 and declined with a half-life of >7 hours. Excretion was primarily in the urine. Thus, TD561 is considered a prodrug of TD562. Other promising members of the prodrug class in OB Pharmaceutical's library are being investigated.
| Drug interactions
The marked stability of TD562 in both liver microsomes and hepatocytes suggests a low probability for drug-drug interactions, especially within the CYP class of enzymes.
| Efficacy, safety, and tolerability data
Clinical studies with TD561 and TD562 have not been conducted to date. 
| Planned studies
| TAK-935 (OV935)
| Introduction and rationale for development
There are significant unmet needs in the treatment of epilepsy disorders, particularly in rare pediatric epilepsies.
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Cholesterol 24-hydroxylase (also known as CYP46A1) is a brain-specific enzyme responsible for cholesterol catabolism. 55 24S-Hydroxycholesterol, the end product of the reaction catalyzed by cholesterol 24-hydroxylase ( Figure 9 ), has recently been characterized as an endogenous positive allosteric modulator of NMDA receptors. 56 Inhibition of cholesterol 24-hydroxylase could provide therapeutic benefits in disorders related to glutamatergic neuronal excitation. Based on this background, TAK-935, an arylcarbonyl heterocyclic compound was identified as a specific cholesterol 24-hydroxylase inhibitor and is being developed as a potential AED with a novel mechanism of action.
| Pharmacology
| Activity profile in experimental seizure and epilepsy models
The anticonvulsant activity of TAK-935 was characterized in several seizure and epilepsy models, including the SCN1A mouse, a murine model of mesial temporal lobe epilepsy, and the mouse PTZ-induced kindling model. In the PTZ (42.5 mg/kg ip) kindling model, the relationship between effects of TAK-935 on kindling retardation and cholesterol 24-hydroxylase inhibition was examined. Osmotic pumps carrying a range of doses of TAK-935 for sc administration were used to achieve robust cholesterol 24-hydroxylase inhibition. Brain 24S-hydroxycholesterol lowering was correlated with cumulative seizure scores (r = −0.682; P < 0.05, Pearson correlation coefficient), indicating that the effects of TAK-935 on kindling acquisition were related to cholesterol 24-hydroxylase inhibition. TAK-935 decreased seizure burden by 39% and 75% at doses of 1 and 10 mg/kg (sc infusion), treatment conditions that reduced brain 24-hydroxy-cholesterol levels by 58% and 92%, respectively. Tested at a treatment condition that decreases brain 24S-hydroxycholesterol by 86%, TAK-935 did not show notable protection from seizures induced acutely by PTZ (60 mg/kg ip).
| Mechanism of action
TAK-935 is a potent competitive inhibitor of cholesterol 24-hydroxylase, an enzyme that is expressed predominantly in the brain, and which plays a role in the homeostasis of brain cholesterol. 55 Cholesterol 24-hydroxylase converts cholesterol to 24S-hydroxycholesterol, which has been found to act as an endogenous positive allosteric modulator of NMDA receptors. 56 
| Toxicology
The standard chronic toxicology package has been completed to allow TAK-935 dosing in humans, including pediatric populations.
| Pharmacokinetics
In a phase I randomized, double-blind, placebo-controlled study, single ascending doses of 15, 50, 200, 600, 900, and 1350 mg of TAK-935 (oral solution) or placebo were administered to 48 healthy subjects under fasted conditions. Eight subjects (six on TAK-935 and two on placebo) were assessed in each cohort. TAK-935 was rapidly absorbed, with median t max values being observed between 0.25 and 0.5 hours after dosing. Exposure to TAK-935 increased disproportionately with increasing doses. In particular, mean C max and AUC ∞ values increased 183-and 581-fold, respectively, over a 90-fold dose increase. The renal excretion of TAK-935 was negligible (≤0.6% of the dose), and terminal half-life generally increased with increasing dose from 0.82 hours after a 15-mg dose to 7.16 hours after a 1350-mg dose ( Figure 10 ). Plasma 24S-hydroxycholesterol concentrations generally decreased with increasing dose (Figure 11 ). In another randomized, double-blind, placebo-controlled study, 40 healthy subjects received ascending oral doses of TAK-935 at doses of 100, 300, or 400 q.d. for 14 days, or 600 mg q.d. or 300 mg b.i.d. for 10 days. Eight subjects (six on TAK-935 and two on placebo) were assessed in each of the five cohorts. At steady state, there was a slightly greater than dose-proportional increase in peak plasma concentrations and exposure, with mean plasma C max values and AUC values during a dosing interval increasing approximately sixfold over a fourfold dose increase. Administration of 100-400 mg doses q.d. for 14 days was associated with rapid absorption (median t max between 0.33 and 0.42 hours), negligible renal excretion (≤0.25% of dose), and rapid elimination with mean terminal half-lives of 3.5-4.8 hours across the dose range of 100-600 mg on day 1 or 14 ( Figure 12 ). Consistent with the short half-lives, there was no apparent accumulation after q.d. dosing. As expected, 300-mg b.i.d. dosing showed a higher mean concentration at the end of the dosing interval at steady state on day 11 compared with 600 mg q.d. Plasma 24S-hydroxycholesterol concentrations generally decreased in a dose-exposure-dependent manner, with steady state reached by day 7 of dosing, and a percentage decrease from baseline of trough plasma 24S-hydroxycholesterol concentration to the extent of about 70% for both the 300 mg b.i.d. and 600 mg q.d. groups. Time-matched areas under the effect curves for 24S-hydroxycholesterol on day 14 decreased from baseline by 47%-63% across the dose range of 100-400 mg q.d. (Figure 13 ).
| Drug interactions
No clinical drug interaction data are currently available. In vitro studies showed that TAK-935 is a major substrate of uridine 5′-diphosphate-glucuronosyltransferases and CYP3A. Thus, strong CYP3A inhibitors and inducers have the potential to alter the pharmacokinetics of TAK-935. TAK-935 is not an inducer of major CYPs, and it is a weak inhibitor of CYPs. Therefore, TAK-935 is not anticipated to alter the pharmacokinetics of CYP substrates at the targeted highest clinical dose regimen of 300 mg b.i.d.
| Efficacy data
Studies to evaluate the clinical efficacy of TAK-935 have not been performed to date. An open-label study in adult patients with developmental and epileptic encephalopathies is ongoing, with safety/tolerability as the primary outcome measure; seizure data are also being collected as the exploratory outcome measure.
| Tolerability and adverse effect profile
In the single oral ascending dose study that evaluated doses up to 1350 mg, TAK-935 was well tolerated. Five (42%) placebo-treated subjects and 14 (39%) TAK-93-treated subjects experienced a total of 13 and 29 treatment emergent adverse events (TEAEs), respectively. No dose relationship was apparent in the incidence of any individual TEAE across the TAK-935 dose groups. The most frequently reported TEAEs were headache (two subjects in the placebo group and three in the TAK-935-treated groups), application-site dermatitis (two in the TAK-935-treated groups), and nausea (two in the TAK-935-treated groups). All TEAEs were considered by the investigator to be mild in intensity. No deaths or serious AEs, no AEs leading to study drug or study visit discontinuation, and no other significant AEs were reported. No clinically significant findings for clinical laboratory tests including hormones (prolactin, growth hormone, cortisol, and thyroid-stimulating hormone), vital signs, physical examination, comprehensive eye examination, or electrocardiographic measurements were observed during the study.
TAK-935 was also found to be generally safe and well tolerated in the multiple-dose study with doses up to 600 mg q.d. or 300 mg b.i.d. for 10 days. A total of 45 TEAEs were reported in 14 of the 30 TAK-935-dosed subjects (47%), with 31 events reported in 13 subjects (43%) being considered related to TAK-935. The majority of the TAK-935-related TEAEs were classified as CNS disorders and psychiatric disorders by System Organ Class according to the MedDRA classification system. The majority of TEAEs were of mild intensity, as reported in 12 TAK- 935-dosed subjects. All reported TEAEs resolved without treatment before study exit on day 15. There were two AEs in two subjects that led to study drug discontinuation. The first was mental confusion of mild intensity in a subject receiving TAK-935 300 mg b.i.d., and the second was an event of acute psychosis of severe intensity that occurred in a subject receiving TAK-935 600 mg q.d. As a result, dosing in the remaining subjects in the TAK-935 600 mg q.d. cohort and the TAK-935 300 mg b.i.d. cohort was stopped on day 11. The subsequent cohort was initiated at 400 mg q.d. for 14 days and completed the study with additional safety monitoring measures and stopping rules. The mental confusion and the acute psychosis noted above in a subject receiving TAK-935 were reversible and considered to be on-target mechanism of action effects occurring at nontitrated doses in the healthy volunteers. In clinical studies in patients with developmental and epileptic encephalopathy, TAK-935 will be uptitrated to the target dose for additional tolerability.
| Planned studies
Studies are being planned to initiate in 2018 testing of TAK-935 in pediatric patients 2 to <18 years of age in several different types of developmental and epileptic encephalopathies.
| XEN901
James P. Johnson, Jr., Gregory N. Beatch, Thilo Focken, Jay A. Cadieux, Rostam Namdari, Christoph Dehnhardt, Mike Grimwood, Kristen Burford, Abid Hasan, Luis Sojo, Kuldip Khahk, Samuel Goodchild, Parisa Karimi Tari, Celine Dube, Heather Kato, Lena Legkaia, Ernesto Aycardi, Robin Sherrington, Simon N. Pimstone, Y. Paul Goldberg, Raymond Winquist, James Empfield, and Charles J. Cohen Xenon Pharmaceuticals Inc., Burnaby, Canada
| Introduction and rationale for development
XEN901 is a potent and highly selective Nav1.6 (voltagegated sodium channel type VIII; SCN8A) inhibitor. It is an arylsulfonamide with physicochemical properties that permit efficient brain penetration. XEN901 binds to voltage sensor domain IV and inhibits recovery from inactivation. Due to this profile, it represents a potential first-in-class antiseizure drug and in preclinical studies has shown a higher therapeutic index than other antiseizure drugs targeting sodium channels. Mature CNS neurons predominantly express three voltage-gated sodium channels: Nav1.1 (SCN1A), Nav1.2 (SCN2A), and Nav1.6 (SCN8A). Nav1.1 is the dominant isoform in inhibitory interneurons, and blockade of Nav1.1 is expected to be proconvulsant, as patients with heterozygous null mutations in the SCN1A gene present with early infantile epileptic encephalopathy 6 (EIEE6; Dravet syndrome).
57 Nav1.2 and Nav1.6 are both highly expressed in excitatory neurons, and knockdown of Nav1.6 suppresses kainate-induced seizures in mice. 58 Gain-of-function mutations in Nav1.6 have been linked to a severe childhood epileptic encephalopathy (EIEE13), 59 and a selective inhibition of the Nav1.6 channel would directly address the underlying etiology. Although nonselective sodium channel blockers are widely used as antiseizure drugs, these compounds generally require relatively high plasma concentrations for efficacy and have a low therapeutic index. XEN901 targets a novel binding site in voltage sensor domain IV that enables improved selectivity and hence an improved preclinical safety profile. ). These mice display augmented Nav1.6 currents at the neuronal level and signs of epilepsy including reduced seizure thresholds, spontaneous seizures, and sudden unexpected death in epilepsy. 60 A relatively weak stimulus elicits seizures in transgenic mice, but not wild-type, affording a target engagement assay for the inhibition of mNav1.6. As expected from the relative potency for block of Nav1.6, XEN901 is~1000 times more potent than phenytoin or carbamazepine in this 6-Hz assay. Robust anticonvulsant activity (70% inhibition) is achieved when total brain concentration is comparable to the IC 50 for Nav1.6. XEN901 was also evaluated in wild-type mice and rats using the MES test. Currently used anticonvulsants that are sodium channel antagonists are active in these assays, and these have been predictive of clinical efficacy. The ED 70 of XEN901 in mice and rats is 10 and 6 mg/kg po, respectively. The potency of XEN901 is enhanced by repeat po dosing of mice for 7 days, where the EC 70 (plasma concentration) is reduced sixfold following repeat dosing to 20 nmol/L.
| Mechanism of action
XEN901 inhibits human Nav1.6 current with an IC 50 < 100 nmol/L and is >100-fold selective against all other human voltage-gated Nav subtypes (Nav1.1-1.7) in voltage clamp studies with heterologously expressed sodium channels. The potency of inhibition of Nav1.6 was unchanged by seven of eight EIEE13 mutations and was reduced sevenfold by a mutation within the binding site for XEN901. Inhibition is highly state-dependent such that block of inactivated channels is >1000-fold more potent than those in the rested state. The compound is >20-fold selective against a panel of >50 targets including receptors, enzymes, and transporters.
| Toxicology
A comprehensive toxicological evaluation following oral administration has been completed for XEN901 that included non-GLP single-and repeat-dose studies and 28-day pivotal GLP toxicology studies in rats and dogs along with a GLP battery of genotoxicity studies. This toxicology package of studies supported the start of clinical trials.
In the GLP toxicology assessment, q.d. oral administration of XEN901 to rats at doses of 5, 25, or 125 mg/kg/d for 28 days was well tolerated and did not result in mortality or any adverse findings. Consequently, under the conditions of this study, the NOAEL of XEN901 was determined to be 125 mg/kg/d, 20-fold higher than the ED 70 . XEN901 was assessed in a 28-day repeat-dose GLP toxicology study in beagle dogs at doses of 0.5 or 2 and 6 mg/kg q.d. po with a 28-day recovery period. XEN901 was well tolerated and did not result in mortality or adverse effects, except for transient decreases in body weight for both males and females at 6 mg/kg/d, which was associated with a transient decrease in food consumption and vomiting. The NOAEL for XEN901 in dogs could not be precisely established (>2 and <6 mg/ kg/d) due to body weight decrease at 6 mg/kg/d. The NOAEL based on all other end points (eg, CNS toxicity and histopathology) is deemed to be 6 mg/kg/d. The noobserved-effect level for XEN901 was determined to be 2 mg/kg/d, associated with a C max and AUC 0-24 h of 1790 ng/mL and 5340 ng/mL·h, respectively, in males; and 1400 ng/mL and 4150 ng/mL·h, respectively, in females. In addition, XEN901 was negative across a standard panel of GLP genotoxicity assays and no safety pharmacology concerns were noted in animal studies.
Based on preclinical pharmacology and toxicology studies and comparison of these data with those of the nonselective sodium channel blockers phenytoin, carbamazepine, and lacosamide, XEN901 has the potential for a best-inclass safety margin.
| Pharmacokinetic and metabolic profile
The pharmacokinetics of XEN901 has been evaluated in mice, rats, dogs, and monkeys. Oral bioavailability is modest in mice (about 10%), but it is significantly higher in rats, dogs, and monkeys, approaching 100%. Absorption is relatively rapid, and C max values are typically achieved between 0.5-2 hours after oral dosing. The half-life was 2 hours in dogs and monkeys and typically ranged between 0.5 and 4 hours in mice and rats, respectively.
The stability of XEN901 in liver microsomes is speciesdependent, with the greatest stability in human microsomes. The in vitro metabolic stability ranking in terms of percentage remaining after 60 minutes of incubation was monkey and dog (~1%) < rat (~8%) < human (~40%). In vitro and in vivo metabolic profiling studies indicate that there are no unique human metabolites.
XEN901 is metabolized by CYP3A4, CYP2D6, and to a lesser extent CYP2C9. XEN901 inhibited CYP2D6 with an IC 50 of 7.5 μmol/L, whereas IC 50 values for the inhibition of CYP1A2, CYP2C9, CYP2C19, and CYP3A4 were >20 μmol/L.
| Ongoing and planned clinical studies
A double-blind, placebo-controlled, adaptive design phase I trial evaluating safety, tolerability, and pharmacokinetics after single and multiple b.i.d. dosing is in progress. The study also includes assessment of the potential for a food effect on the pharmacokinetic profile. The study initially establishes the pharmacokinetic profile of a powder-in-capsule formulation and then transitions to evaluation of a phase II ready tablet formulation.
Application for initiation of a phase II efficacy and tolerability study is anticipated to be made by the end of 2018. XEN901 is expected to have utility in both focal seizures and pediatric epileptic encephalopathies, especially EIEE13 as described above. XEN1101 is an NCE that enhances activation of neuronal Kv7.2-7.5 (KCNQ2-5) potassium channels, which constitute the molecular components of the slow activating/ deactivating voltage-gated M-current. Initially described in the EILAT XIII progress report as 1OP-2198, 7 this second generation Kv7 channel opener is more potent and target-selective than the first generation Kv7 channel modulator retigabine, which has been shown to be clinically effective in the treatment of focal epilepsy. Retigabine was withdrawn from the market for commercial reasons following black-box warnings related to discoloration of skin, lips, and nails and retinal pigmentary changes that appear to be related to formation of retigabine-retigabine dimers. 61 XEN1101 is a metabolically more stable Kv7 opener that cannot form the pigmented dimer and therefore is expected to have improved safety over retigabine. XEN1101 is inactive on Kv7.1 (cardiac Kv LQT1 channel). XEN1101 is a Biopharmaceutics Classification System class 2 small molecule (molecular weight < 400 g/mol) designed to be more potent than retigabine. It is structurally unrelated to XEN901 and any currently marketed AED.
| XEN1101
| Pharmacology
XEN1101 is effective in several in vivo rodent models of electrically and chemically induced seizures and exhibits a selectivity >100-fold for Kv7 channels over other ion channels and receptors. Additional research on the effect of XEN1101 on G-V activation concentrationresponse curves in vitro in CHO cell lines stably expressing heteromeric Kv7.2/7.3 and Kv7.3/7.5 potassium channels and homomeric Kv7.4 channels demonstrates increased potency compared to retigabine. Based on calculated EC 50 , XEN1101 was found to be~4-fold selective for Kv7.2/7.3 over Kv7.3/7.5 and Kv7.4 channels, with EC 50 values of 27 nmol/L versus 94 nmol/L and 113 nmol/L, respectively. It was hypothesized that a 4-mV shift in channel activation of Kv7.2/7.3 was the minimal shift needed for retigabine to cause a clinically significant reduction in seizures. 62 Compared to retigabine (300 nmol/L), XEN1101 has been found to produce a 4-mV shift of activation at approximately 6 nmol/L.
| Toxicology
Multiple dosing (28-day) oral toxicology studies were supportive of initiating first-in-human clinical studies. Furthermore, there were no safety pharmacology or genotoxicity signs that prevented the initiation of clinical development. XEN1101 has also completed 4-month repeat-dose toxicology studies in rats and cynomolgus monkeys in support of phase II clinical trials with a 12-week maintenance period for efficacy assessments. The preliminary results indicate that clinical observations were consistent with the exposure-response relationship seen in the 28-day oral toxicity studies.
| Preclinical pharmacokinetic and drug interaction studies
Studies in nonhuman primates showed a favorable pharmacokinetic profile; for example, a single oral gavage dose of 1 mg/kg resulted in a C max of 54.2 ng/mL in male and 68.7 ng/mL in female monkeys, with an elimination halflife of 10.2 and 8.4 hours, respectively. Although XEN1101 was found to be highly metabolically stable in human cryopreserved hepatocytes (82.4% remaining after 60 minutes), 39.1% of XEN1101 metabolism was inhibited by the selective CYP3A4 inhibitor ketoconazole at 2 μmol/L, suggesting a role for CYP3A4-mediated oxidation in XEN1101 metabolic clearance. However, there was no clinically meaningful induction of the pregnane X nuclear receptor (PXR), which is associated with CYP3A4 expression levels, at relevant concentrations (0.1-1 μmol/L).
XEN1101 at concentrations (3 μmol/L) multiple folds above anticipated efficacious concentration levels did not inhibit CYP1A2, CYP2C9, CYP2C19, CYP2D6, and CYP3A4 directly, nor did it cause time-dependent inhibition. This suggests a low potential for drug-drug interactions through the inhibition of these CYP isoenzymes.
| Phase I studies
The first-in-human study was a single and multiple ascending dose study with an immediate-release formulation in healthy male and female volunteers, with a starting dose of 5 mg. The study evaluated the pharmacokinetics and tolerability of XEN1101 and included a food effect cohort. Single doses of 5, 15, 20, and 30 mg and repeat dosing of 15 mg given q.d. were assessed. XEN1101 was well tolerated with typical transient AEs for this class of drugs, eg, mild to moderate drowsiness and dizziness. There were no serious AEs. Exposure of 15 mg given q.d. in the fasting state for 7 days (n = 6) increased from day 1 to day 7, with C max increasing fivefold and AUC 24 h increasing at least sixfold without a shift in t max , which was 2.5 hours. Elimination is biphasic, with an estimated terminal half-life > 5 days and a functional half-life of 1-2 days (ie, leading to accumulation to steady state within 7-10 days), which implies mild to moderate (~25%) peak to trough fluctuations with q.d. dosing with an immediate-release tablet. The second stage of the phase I trial is ongoing and includes single and multiple doses of an immediate-release tablet formulation.
Transcranial magnetic stimulation (TMS) pulses produce characteristic deflections in the EEG signal, which can be used to assess cortical excitability and to measure the effect of drugs acting in the brain. TMS can also be used to determine the resting motor threshold for eliciting a minimal muscle response, as a biomarker of neuronal excitability. Retigabine, a Kv7.2/7.3 activator, has been shown to elevate resting motor threshold in healthy volunteers. 63 A pilot TMS substudy was completed during the phase I study to determine an optimal sample size and dosing regimen for a definitive TMS study, which is intended to characterize the effects of XEN1101 on measures of cortical excitability in comparison with placebo in a double-blind, randomized, placebo-controlled crossover design. The TMS crossover study is currently ongoing and expected to be complete in late 2018. In the pilot TMS study, XEN1101 (20 mg single dose po) had a twofold greater effect on resting motor threshold than that reported for retigabine (400 mg po). 63 Furthermore, XEN1101 modulated TMS-EEG signals of cortical excitability in the healthy volunteers to a similar degree as previously shown for lamotrigine and levetiracetam. 64 Further studies will need to be performed to determine whether these encouraging TMS-EEG findings may be predictive biomarkers of potential treatment response in patients with epilepsy.
| CONCLUSIONS
The gradual introduction of second generation AEDs over the past 20 years has greatly expanded the pharmacological armamentarium against epilepsy, allowing improved individualization of treatment. The proportion of people with epilepsy who fail to achieve seizure freedom on currently available treatments, however, has not been reduced substantially by second generation AEDs, and the search for newer and more effective medications continues. Advances in this area are made possible by application of a wide range of strategies in drug discovery, including the search for compounds acting on traditional targets with greater selectivity or with novel interaction modalities, the pursuit of innovative targets known to be involved in ictogenesis or epileptogenesis, and the effort to identify treatments directed at the etiology, rather than the symptoms, of specific epilepsy syndromes. Promising results from ongoing research are described in the review of the compounds listed in this article, which illustrate many innovative approaches to drug development. For example, some compounds are being combined with traditional antiepileptic drugs based on evidence of synergism in seizure models, some act as inhibitors of enzymes involved in modulation of neuronal activity, and some interact in novel ways with excitatory receptors or ion channels. Some of these compounds are now being investigated in clinical trials in patients with epilepsy, and hopefully will ultimately lead to improved therapeutic options for use in clinical practice. XEN901: All authors are employed by Xenon Pharmaceuticals (J.P.J., T.F., C.De., M.G., K.B., A.H., L.S., K.K., S.G., P.K.T., C.Du., R.W., J.E., C.J.C.). XEN1101: G.N.B., R.N., J.A.C., Y.M., C.L., S.H.K., S.N.P., E.A., R.S., and Y.P.G. are employees of Xenon Pharmaceuticals. C.C. is a Xenon consultant and is President and Chief Scientific Officer of 1st Order Pharmaceuticals, the licensor of XEN1101 to Xenon. I.P. and M.P.R. are employees of King's College London, and generated the TMS data reported in the XEN1101 section in their laboratory at King's College London, supported by funding from Xenon Pharmaceuticals.
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